Inhibition of PI3K/AKT/mTOR signaling through pharmacologic and genetic approaches induces antiproliferative effects on certain NSCLC cell lines [17]–[21] and in lung cancer mouse models [25], [28]. This evidence concerns the gene MTOR and lung carcinoma.